


CLAIMS

1. A compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



wherein:

- 10 R^1 represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl, $-S(O)_n C_{1-6}$ alkyl, $-S(O)_n C_{1-6}$ haloalkyl and pentafluorothio;
- 15 R^2 represents hydrogen, halo, cyano, nitro, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl, C_{2-6} haloalkynyl, $-S(O)_n C_{1-6}$ alkyl, $-S(O)_n C_{1-6}$ haloalkyl, $-(C_{0-3}$ alkylene)- C_{3-8} cycloalkyl, C_{1-6} alkanoyl, optionally substituted by C_{1-6} alkoxy, C_{1-6} haloalkanoyl, optionally substituted by C_{1-6} alkoxy, phenyl, het, $-(C_{0-3}$ alkylene)- $N(R^a)R^b$, $-(C_{0-3}$ alkylene)- $C(O)NR^aR^b$ or $-(C_{0-3}$ alkylene)- $N(R^c)C(O)R^6$;
- 20 R^3 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, $-(C_{0-3}$ alkylene)- C_{3-8} cycloalkyl, $-(C_{1-3}$ alkylene)- $S(O)_n C_{1-6}$ alkyl, $-(C_{1-3}$ alkylene)- $S(O)_n C_{1-6}$ haloalkyl, $-(C_{0-3}$ alkylene)- $N(R^a)R^b$, $-(C_{0-3}$ alkylene)-phenyl, $-(C_{0-3}$ alkylene)-het, $-(C_{2-3}$ alkenylene)-phenyl, $-(C_{2-3}$ alkenylene)-het, C_{1-6} alkanoyl, C_{1-6} haloalkanoyl or $-N(R^c)CO_2R^6$;
- 25 R^4 represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-(C_{0-3}$ alkylene)- R^7 or $-(C_{1-3}$ alkylene)- R^8 ;
- or R^3 and R^4 taken together with the nitrogen and sulphur atoms to which they are
- 30 attached form a 4 to 7-membered ring;

R^5 represents hydrogen, hydroxy, halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ or $-N(R^{12})R^{13}$;

5 R^6 represents C_{1-6} alkyl or C_{1-6} haloalkyl;

R^7 represents C_{3-8} cycloalkyl, $-S(O)_nR^9$, phenyl, het, $-CO_2R^6$ or $C(O)N(R^a)R^b$;

R^8 represents hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, cyano, $-N(R^a)R^b$ or $-O-C(O)R^6$;

10

R^9 represents C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, $-N(R^a)R^b$, phenyl or het;

R^{10} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

15 R^{11} represents hydrogen, hydroxy, C_{1-3} alkoxy, $-N(R^a)R^b$, phenyl, het or C_{3-8} cycloalkyl, with the proviso that $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$ is not $-N=CH_2$;

R^{12} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl or C_{1-6} haloalkenyl;

20 R^{13} represents hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkenyl, C_{1-6} haloalkenyl C_{3-8} cycloalkyl, phenyl, het, $-(C_{1-6}alkylene)-R^{14}$, $-C(O)_pR^{15}$ or $-CON(R^{16})(C_{1-6}alkylene)-R^{17}$;

R^{14} represents hydroxy, C_{1-3} alkoxy, C_{1-3} haloalkoxy, C_{3-8} cycloalkyl, phenyl, het or $-N(R^a)R^b$;

25

R^{15} represents C_{1-6} alkyl, C_{1-6} haloalkyl or $-(C_{1-6}alkylene)-C_{1-3}$ alkoxy;

R^{16} represents hydrogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

30 R^{17} represents hydrogen or $N(R^a)R^b$;

R^a and R^b independently represent hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl or C_{2-6} haloalkenyl, or R^a additionally represents $-(C_{0-3}alkylene)-C_{3-8}$ cycloalkyl, $-(C_{0-3}alkylene)-phenyl$ or $-(C_{0-3}alkylene)-het$, or together R^a and R^b form a 4- to 7-

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₁₋₆ alkoxy and C₁₋₆haloalkoxy;

5 R^c represents hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ haloalkenyl, -(C₀₋₃alkylene)-C₃₋₈ cycloalkyl, -(C₀₋₃alkylene)-phenyl or -(C₀₋₃alkylene)-het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

15 where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₁₋₆ alkenyl, C₁₋₆haloalkenyl, C₁₋₆alkoxy, C₁₋₆haloalkoxy, C₃₋₈ cycloalkyl, C₁₋₆ alkanoyl, C₁₋₆ haloalkanoyl, C₁₋₆ alkylcarbonyloxy, C₁₋₆ alkoxy carbonyl and NR^aR^b;

20

where C₃₋₈cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆ alkenyl, C₁₋₆haloalkenyl, hydroxy, C₁₋₆alkoxy and C₁₋₆haloalkoxy; and

25

where any alkylene or alkenylene group may be optionally substituted by one or more halo.

30

2. A compound according to claim 1, wherein R¹ is a phenyl group which bears chloro substituents at the 2- and 6-positions, and a substituent at the 4-position selected from trifluoromethyl, difluoromethoxy, trifluoromethoxy, trifluoromethylthio and pentafluorothio.

3. A compound according to claim 1 or 2, wherein R^2 is selected from hydrogen, cyano, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, e.g. cyclopropyl, C_{1-6} alkanoyl and $-C(O)N(R^a)R^b$.

5 4. A compound according to claim 3, wherein R^2 is cyano.

5. A compound according to any one of claims 1-4, wherein R^3 is selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-8} cycloalkyl, $-(C_{1-3}\text{alkylene})-S(O)_nC_{1-6}\text{alkyl}$, $-N(R^a)R^b$, C_{1-6} alkanoyl, $-N(R^a)CO_2R^6$, phenyl, optionally substituted by one or more halo, and benzyl.

10

6. A compound according to claim 5, wherein R^3 is methyl.

7. A compound according to any one of claims 1-6, wherein R^4 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, $-(C_{0-3}\text{alkylene})-C_{3-8}$ cycloalkyl, cyanomethyl, 2-
15 hydroxyethyl, $-(C_{1-2}\text{alkylene})\text{-het}$, $-(C_{0-3}\text{alkylene})\text{-phenyl}$, $-(C_{0-1}\text{alkylene})-S(O)_nR^9$, $-(C_{1-3}\text{alkylene})-O-C(O)R^6$, $-(C_{1-3}\text{alkylene})-C(O)N(R^a)R^b$ and $-CO_2R^6$.

8. A compound according to claim 7, wherein R^4 is selected from hydrogen, methyl, ethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, methylsulfonyl,
20 trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, aminosulfonyl, N,N-dimethylaminosulfonyl, methylsulfonylmethyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, 1-(trifluoromethyl)cyclopropylmethyl, cyanomethyl, methoxycarbonyl, triazolylethyl, pyrimidin-4-ylmethyl, 1,2,4-oxadiazol-3-ylmethyl, pyrazol-3-ylmethyl, 1-methyl-1H-imidazol-2-yl, 5-methyl-isoaxazol-3-ylmethyl, 2-pyridin-4-ylethyl, aminocarbonylmethyl,
25 benzyl and 4-fluorobenzyl.

9. A compound according to any one of claims 1-8, wherein R^5 is selected from hydrogen, halo, C_{1-6} alkoxy, $-N=C(H)R^{11}$, where R^{11} is ethoxy, N,N-dimethyl or phenyl, and $-NR^{12}R^{13}$.

30

10. A compound according to claim 9, wherein R^5 is amino.

11. A compound of formula (I) selected from:

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2-difluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-1,1,1-trifluoro-*N*-methylmethanesulfonamide;

5 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-3,4-difluorobenzenesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(cyclopropylmethyl)methanesulfonamide;

10 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(cyanomethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(pyridin-2-ylmethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-benzylmethanesulfonamide;

15 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-[2-(dimethylamino)ethyl]methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1-(methylsulfonyl)methanesulfonamide;

20 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(2-hydroxyethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-[(methylthio)methyl]methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)cyclopropanesulfonamide;

25 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-[(dimethylamino)sulfonyl]methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

30 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1-phenylmethanesulfonamide;

(*E*)-*N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-2-phenylethylsulfonamide;

N-[5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,1-dioxidoisothiazolidin-2-yl)-1H-pyrazole-3-carbonitrile;

5 N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-1,1,1-trifluoro-N-methylmethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-(cyclopropylmethyl)-1,1,1-trifluoromethanesulfonamide;

10 N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-1,1,1-trifluoro-N-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-cyclobutyl-1,1,1-trifluoromethanesulfonamide;

15 N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-1,1,1-trifluoro-N-methylmethanesulfonamide;

20 N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methanesulfonamide;

25 N-{3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}-N-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-(2,2,2-trifluoroethyl)methanesulfonamide;

30 N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl}-N-[2-(1H-1,2,4-triazol-1-yl)ethyl]methanesulfonamide;

5-amino-4-[bis(methylsulfonyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazole-3-carboxamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl}-N-(methylsulfonyl)methanesulfonamide;

N-{3-acetyl-5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

5 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-{[1-(trifluoromethyl)cyclopropyl)methyl}methanesulfonamide;

10 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)ethanesulfonamide;

methyl 5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl(methylsulfonyl)carbamate;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-methylmethanesulfonamide;

15 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-fluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(1,2,4-oxadiazol-3-ylmethyl)methanesulfonamide;

20 *N*²-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*²-(methylsulfonyl)glycinamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(1*H*-pyrazol-3-ylmethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,3,3,3-pentafluoropropyl)methanesulfonamide;

25 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-pyrrolidin-1-ylethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-morpholin-4-ylethyl)methanesulfonamide;

30 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[(1-methyl-1*H*-imidazol-2-yl)methyl]methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[(5-methylisoxazol-3-yl)methyl]methanesulfonamide;

[{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}(methylsulfonyl)amino]methyl pivalate;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-ethylmethanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-benzylmethanesulfonamide;

5 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(4-fluorobenzyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-1-(methylsulfonyl)ethanesulfonamide;

10 *N*-{5-amino-1-[2-chloro-4-pentafluorothio-phenyl]-3-cyano-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;
5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-(1,1-dioxido-1,2-thiazinan-2-yl)-1*H*-pyrazole-3-carbonitrile;

N-{5-(benzylamino)-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

15 *N*-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-yl}-2-methoxyacetamide;

ethyl 4-[bis(methylsulfonyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-5-ylimidoformate;

20 *N*-{3-cyano-5-[(cyclopropylmethyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-yl}acetamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-methoxy-1*H*-pyrazol-4-yl}methanesulfonamide;

25 *N*-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(methylamino)-1*H*-pyrazol-4-yl]-*N*-(methylsulfonyl)methanesulfonamide;

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[[(dimethylamino)methylene]amino]-1*H*-pyrazol-4-yl])-*N*-(methylsulfonyl)methanesulfonamide;

30 *N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[2-(dimethylamino)ethyl]amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-pyrrolidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-morpholin-4-ylethyl)amino]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

N-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

5 *N*-{5-amino-3-cyclopropyl-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(methylsulfonyl)methanesulfonamide;

N-{5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}methanesulfonamide;

10 *N*-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(pyridin-4-ylmethyl)amino]-1*H*-pyrazol-4-yl}methanesulfonamide;

tert-butyl ({5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}amino)sulfonylcarbamate;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2-pyridin-4-ylethyl)methanesulfonamide;

15 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(pyrazin-2-ylmethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-[(6-aminopyridin-3-yl)methyl]methanesulfonamide;

20 *N*-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-2-oxo-*N*-(2,2,2-trifluoroethyl)propane-1-sulfonamide;

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[3-(dimethylamino)propyl]amino]-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

25 *N*-{3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}sulfamide;

N-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-4-fluoro-*N*-(methylsulfonyl)benzenesulfonamide;

30 *N*-{5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl}-2,4-difluoro-*N*-(methylsulfonyl)benzenesulfonamide;

methyl 3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-ylcarbamate;

N-{5-([(2-aminoethyl)amino]carbonyl)amino}-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

trifluoroacetate salt of *N*-{5-[(2-azetidin-1-ylethyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;
N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2,4-dihydroxyphenyl)methylene]amino)-1*H*-pyrazol-4-yl)-*N*-(2,2,2-

5 trifluoroethyl)methanesulfonamide;

N-{5-chloro-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl}-*N*-(2,2,2-trifluoroethyl)methanesulfonamide; or

N-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[3-(dimethylamino)ethyl]amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;

10 or a pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical or veterinary composition comprising a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, and a suitable excipient or carrier.

15

13. A compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, for use in medical therapy.

14. Use of a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, in the manufacture of a human or animal parasitocidal medicament.

20

15. A method of treating a human or animal parasitic infection comprising administration of a therapeutically acceptable amount of compound according to any one claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof.

25